Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Constantine E Kosmas, Maria D Bousvarou, Andreas Sourlas, Evangelia J Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta & Eliscer Guzman. (2022) Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia. Clinical Pharmacology: Advances and Applications 14, pages 49-59.
Read now
Read now
Constantine E Kosmas, Alba Muñoz Estrella, Andreas Skavdis, Edilberto Peña Genao, Ian Martinez & Eliscer Guzman. (2020) Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Therapeutics and Clinical Risk Management 16, pages 1031-1037.
Read now
Read now
Constantine E Kosmas, Andreas Skavdis, Andreas Sourlas, Evangelia J Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta & Eliscer Guzman. (2020) Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clinical Pharmacology: Advances and Applications 12, pages 191-202.
Read now
Read now
Etienne Khoury, Diane Brisson & Daniel Gaudet. (2020) Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Drug Discovery 15:4, pages 403-414.
Read now
Read now
Articles from other publishers (13)
Alissia Stummer, Robin Ristl, Bernhard Kogler, Melanie Muskovich, Michael Kossmeier & Thomas M. Stulnig. (2023) Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment. Wiener klinische Wochenschrift 135:13-14, pages 375-382.
Crossref
Crossref
Rani Khatib, Neil Angus, Tina B Hansen, Ekaterini Lambrinou, Ercole Vellone, Mutiba Khan & Geraldine A Lee. (2022) Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers. European Journal of Cardiovascular Nursing 21:5, pages 430-437.
Crossref
Crossref
Daniel I Swerdlow, David A Rider, Arash Yavari, Marie Wikström Lindholm, Giles V Campion & Steven E Nissen. (2022) Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovascular Research 118:5, pages 1218-1231.
Crossref
Crossref
A. Gil-Núñez, J. Masjuan, J. Montaner, M. Castellanos, T. Segura, P. Cardona, J.I. Tembl, F. Purroy, J. Arenillas & E. Palacio. (2022) Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance. Neurología (English Edition) 37:2, pages 136-150.
Crossref
Crossref
A. Gil-Núñez, J. Masjuan, J. Montaner, M. Castellanos, T. Segura, P. Cardona, J.I. Tembl, F. Purroy, J. Arenillas & E. Palacio. (2022) Inhibidores de la proproteína convertasa subtilisina/kexina tipo 9 (iPCSK9) en la prevención secundaria de episodios vasculares en pacientes con ictus isquémico: Documento de consenso y aplicaciones prácticas. Neurología 37:2, pages 136-150.
Crossref
Crossref
Jennifer Hardy, Stephanie Niman, Edward Pereira, Todd Lewis, Jessica Reid, Rushab Choksi & Rebecca F. Goldfaden. (2021) A Critical Review of the Efficacy and Safety of Inclisiran. American Journal of Cardiovascular Drugs 21:6, pages 629-642.
Crossref
Crossref
Cristina Barale, Elena Melchionda, Alessandro Morotti & Isabella Russo. (2021) PCSK9 Biology and Its Role in Atherothrombosis. International Journal of Molecular Sciences 22:11, pages 5880.
Crossref
Crossref
Domenico R. Nastasi, Joseph V. Moxon, Richard Norman, Alexandra F. Trollope, Sophie Rowbotham, Frank Quigley, Jason Jenkins & Jonathan Golledge. (2021) The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease. Journal of Vascular Surgery 73:4, pages 1396-1403.e3.
Crossref
Crossref
A.B. Sumarokov. (2021) Non-compliance with treatment in patients with hyperlipidemia as a risk factor of cardiovascular disease. Kardiologicheskii vestnik 16:1, pages 28.
Crossref
Crossref
Ekaterini Lambrinou, Martha Kyriakou, Ioanna Lakatamitou, Neil Angus, Rani Khatib, Ercole Vellone, Abigail Barrowcliff, Tina Birgitte Hansen & Geraldine A Lee. (2020) An integrative review on facilitators and barriers in delivering and managing injectable therapies in chronic conditions: A part of the ACNAP project ‘injectable medicines among patients with cardiovascular conditions’. European Journal of Cardiovascular Nursing 19:8, pages 663-680.
Crossref
Crossref
Vivencio Barrios, Carlos Escobar, Vicente Arrarte, Eusebio García, María Rosa Fernández, Luis Miguel Rincón & Cecilia Roldán. (2020) Primer registro nacional sobre la efectividad y seguridad de evolocumab en la práctica clínica en pacientes atendidos en cardiología en España. Estudio RETOSS-CARDIO. Clínica e Investigación en Arteriosclerosis 32:6, pages 231-241.
Crossref
Crossref
Vivencio Barrios, Carlos Escobar, Vicente Arrarte, Eusebio García, María Rosa Fernández, Luis Miguel Rincón & Cecilia Roldán. (2020) First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study. Clínica e Investigación en Arteriosclerosis (English Edition) 32:6, pages 231-241.
Crossref
Crossref
Ning Kam, Kanila Perera, Ella Zomer, Danny Liew & Zanfina Ademi. (2020) Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. PharmacoEconomics 38:9, pages 1007-1020.
Crossref
Crossref